Sentence: Here we report the results of a multicenter retrospective trial evaluating ASCT in patients with transformed lymphoma using the Z-BEAM conditioning regimen , which combines yttrium-90-labeled ibritumomab tiuxetan ( Zevalin ) with high-dose BEAM ( carmustine , etoposide , cytarabine , melphalan ) chemotherapy .
Drug combination annotation:
[{'class': 'POS', 'spans': ['ibritumomab tiuxetan', 'carmustine', 'etoposide', 'cytarabine', 'melphalan'], 'is_context_needed': True}]